シリコンエラストマーから金属イオンの放出を調節するために,水性製薬エキシピエントの使用
Xin Shen1, Xinyu Zhao1, Clare F McCoy1
1School of Pharmacy, Queen's University Belfast, Belfast, UK.
Drug delivery
|August 21, 2025
まとめ
この研究では,シリコンの環から金属イオンが放出され,薬剤的な補助物質が使われています. 補助剤は銅と亜鉛イオンの放出を著しく増加させ,非ホルモン避妊と抗菌剤の治療の可能性を示した.
科学分野:
- バイオマテリアル科学
- ポリマー化学
- 薬物投与システム
背景:
- シリコンエラストマー (ポリメチルシロキサン) は,薬物投与装置に広く使用されている生物適合性のある生物分解性のないポリマーです.
- 現在のシリコンベースの製品は,水害性のある薬物を供給します. 銅や亜鉛のような金属イオンの制御された放出は,溶解性が低いため,依然として困難です.
- 非ホルモン避妊と抗菌剤治療のための多目的性輪の開発には,金属イオンの放出が強化される必要があります.
研究 の 目的:
- シリコンエラストマー装置から銅 (Cu2+) と亜鉛 (Zn2+) イオンをインビトロで放出する方法を調査する.
- 常用医薬品の補助物質と金属ナノパウダーまたは塩を併用することで,イオン放出力学への影響を評価する.
主な方法:
- 銅/亜鉛ナノパウダー,硫酸銅,または亜鉛アセテートを加固シリコンエラストマーに組み込む.
- 医薬品のエキシピエンツ:ゼラチン,ポリビニルピロリドン,サクロース,ヒドロキシプロピルメチルセルロースと併用する.
- シリコンマトリックスからのCu2+とZn2+イオン拡散を定量化するためのインビトロ放出試験.
主要な成果:
- 銅/亜鉛ナノパウダーと塩はシリコンエラストマーにうまく組み込まれました.
- 二価金属塩で満たされたシリコンエラストマーは,ナノパウダーで満たされたものと比較して約100倍のイオン放出を示した.
- ゼラチン,ポリビニルピロリドン,サクロース,およびヒドロキシプロピルメチルセルロースの組み込みにより,Cu2+/Zn2+イオンの放出が30倍まで増加した.
- イオン放出が増加し,シリコン弾性物質の吸収と膨張が増加した.
結論:
- 製薬用補助物質は,シリコン弾性体装置からの金属イオン放出を大幅に強化することができます.
- 放出量が増加するメカニズムは,補助剤の種類と濃度によって影響を受け,水吸収と装置の腫れによるものです.
- このアプローチは,治療や避妊用の金属イオンを局所的に供給するシリコンベースの高度な輪の開発に期待されます.
関連する概念動画
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


